drugset / Trial / NCT01186809

Cytokine Induced Killer (CIK) Cells In Leukemia Patients

NCT01186809 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the Phase IIA study are to: 1. define the safety profile 2. evaluate the efficacy of a sequential infusion of unmanipulated Donor Lymphocyte Infusions (DLI) and Cytokine Induced Killer (CIK) cells for the treatment of molecular, cytogenetic or hematologic relapse after hematopoietic stem cell transplantation and The progression free survival and the overall survival after the sequential infusion of Donor Lymphocyte Infusions (DLI) and Cytokine Induced Killer(CIK) cells.

Timeline

Start
2009-07
Primary completion
2016-09
Completion
2017-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytokine Induced Killer (CIK) cells Cell therapy 1e+06 cells/kg —
Subject Cytokine Induced Killer (CIK) cells Cell therapy 5e+06 cells/kg —
Subject Cytokine Induced Killer (CIK) cells Cell therapy 1e+07 cells/kg —